LZLian Zhao

Lian Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lian Zhao has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Haibo Yu

    Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China

    3 shared publications
  • Jing Yang

    Central Laboratory, Hunan Provincial Tumor Hospital, the Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, Hunan 410013, China

    3 shared publications
  • Anliu Tang

    Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China

    2 shared publications
  • Feiyan Ai

    Department of Gastroenterology, The Third Xiangya Hospital of Central South University; Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Changsha, Hunan, People's Republic of China

    2 shared publications
  • Fen Liu

    Department of Gastroenterology, The Third Xiangya Hospital of Central South University; Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Changsha, Hunan, People's Republic of China

    2 shared publications
  • Guiyuan Li

    Central Laboratory, Hunan Provincial Tumor Hospital, the Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, Hunan 410013, China

    2 shared publications

Latest Publications

  • Open Access

    Inhibition of lncRNA NEAT1 suppresses the inflammatory response in IBD by modulating the intestinal epithelial barrier and by exosome-mediated polarization of macrophages

    by Rui Liu, Anliu Tang, Xiaoyan Wang, Xiong Chen, Lian Zhao, Zhiming Xiao, Shourong Shen

    Inflammatory bowel disease (IBD) is a multifactorial inflammatory disease, and increasing evidence has demonstrated that the mechanism of the pathogenesis of IBD is associated with intestinal epithelial barrier injury. Long non‑coding RNAs (lncRNAs) are a class of transcripts >200 nucleotides in length with limited protein‑coding capability. Nuclear paraspeckle assembly transcript 1 (NEAT1) is a recently identified nuclear‑restricted lncRNA, which localizes in subnuclear structures, termed paraspeckles, and is involved in the immune response in a variety of ways. However, the function of NEAT1 in IBD remains to be fully elucidated. In the present study, reverse transcription‑quantitative polymerase chain reaction assays were performed to determine the expression levels of NEAT1 lncRNA in IBD serum samples and tissues. Furthermore, the effect of NEAT1 on the cell permeability of colon cells was investigated via determination of trans‑epithelial electrical resistance as well as performance of western blot and immunofluorescence assays. In addition, dextran sodium sulfate assays were performed to investigate the effect of downregulation of NEAT1 in IBD of mice. The present study detected the expression levels of NEAT1 in IBD cells and animal models to examine the changes in intestinal epithelial cell permeability following inhibition of the expression of NEAT1. In addition, phenotypic transformation was examined following different treatments in epithelial cells and macrophages. The results suggested that the expression of NEAT1 was high in IBD and was involved in the inflammatory response by regulating the intestinal epithelial barrier and through exosome‑mediated polarization of macrophages. The downregulation of NEAT1 suppressed the inflammatory response by modulating the intestinal epithelial barrier and through exosome‑mediated polarization of macrophages in IBD. The results of the present study revealed a potential strategy of targeting NEAT1 for IBD therapy.


  • Open Access

    Curative versus palliative treatments for colorectal cancer with peritoneal carcinomatosis: a systematic review and meta-analysis

    by Wenqiong Wu, Shipeng Yan, Xianzhen Liao, Haifang Xiao, Zhongxi Fu, Lizhang Chen, Jinsong Mou, Haibo Yu, Lian Zhao, Xiangguo Liu

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Wenqiong Wu1, Shipeng Yan2, Xianzhen Liao2, Haifang Xiao2, Zhongxi Fu3, Lizhang Chen4, Jinsong Mou5, Haibo Yu6, Lian Zhao7, 8 and Xiangguo Liu2 1Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan Province, China 2Department of Cancer Prevention and control, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan Province, China 3Department of Chronic Diseases Prevention and Control, Centers for Disease Control and Prevention of Hunan, Changsha, Hunan Province, China 4Department of Epidemiology and Health Statistics, School of Public Health, Central South University, Changsha, Hunan Province, China 5Department of Epidemiology and Health Statistics, Changsha Medical University, Changsha, Hunan Province, China 6Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China 7Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China 8Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Changsha, Hunan Province, China Correspondence to: Shipeng Yan, email: shipengyan86@126.com Keywords: meta-analysis, cytoreductive surgery, intraperitoneal chemotherapy, colorectal cancer, peritoneal carcinomatosis Received: June 08, 2017 Accepted: October 05, 2017 Published: October 20, 2017 ABSTRACT The objective of this study was to provide an up-to-date summary of the current evidence that may be useful for updating guidelines. We comprehensively searched the published literatures and conferences for studies that compared curative with palliative treatments in colorectal cancer patients with peritoneal metastasis. The primary outcomes considered in this study were three- and five-year overall survival rates. We pooled data across studies and estimated summary effect sizes. Overall, patients who received curative treatments had improved three-year survival (hazard ratio (HR), 2.19 [95% CI, 1.83 to 2.62]) and five-year survival (HR, 2.22 [95% CI, 1.83 to 2.69]) compared with those who received palliative treatments. Patients who received curative treatments had an increased risk of treatment-related morbidity (odds ratio (OR), 2.90 [95% CI, 2.02 to 4.17]), but there was no significant difference in treatment-related mortality between patients who received curative treatments and those who received palliative treatments (OR, 1.46 [CI, 0.62 to 3.47]). Curative treatments improved overall survival in colorectal cancer patients with peritoneal metastasis and did not increase the risk of treatment-related mortality. Curative treatments were associated with a higher risk of treatment-related morbidity. These data highlight the importance for further investigation aimed at prevention of treatment-associated morbidity.


  • Open Access

    Infliximab enhances the therapeutic effects of 5-fluorouracil resulting in tumor regression in colon cancer

    by Fen Liu, Feiyan Ai, Li Tian, Shaojun Liu, Lian Zhao, Xiaoyan Wang

    Colon cancer (CC) is among the most common malignant diseases with a dismal survival. Tumor necrosis factor-alpha (TNF-α) has been identified as a therapeutic target in various cancers, and anti-TNF-α treatment has shown promising effects in different cancer models. However, if TNF-α can be targeted in CC, the therapeutic values of anti-TNF-α treatment in CC remain unknown. Our study indicated that TNF-α is highly expressed in CC cell lines and patient tumor samples. High expression of TNF-α is an independent adverse prognosticator of CC. Targeting the TNF-α by its antibody infliximab induced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity and enhanced apoptosis leading to cell death. The combination of infliximab with 5-fluorouracil showed better responses in vitro and in vivo than 5-fluorouracil alone. In conclusion, this study identified TNF-α as a target of CC and anti-TNF-α treatment synergized with chemotherapy leading to a better outcome in preclinical models.


  • [Association between serum levels of S100A8/S100A9 and clinical features of colorectal cancer patients].

    by Peng Shu, Lian Zhao, Jing Wagn, Xiaohua Shen, Xuemei Zhang, Shourong Shen, Jian Ma, Xiayu Li

    To analyze the association between serum levels of S100A8/S100A9 and clinicopathological features of colorectal cancer patients.


  • Open Access

    The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer

    by Lian Zhao, Haibo Yu, Shuijing Yi, Xiaowei Peng, Peng Su, Zhiming Xiao, Rui Liu, Anliu Tang, Xiayu Li, Fen Liu, et al.

    The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer


  • Open Access

    The copy number of Epstein-Barr virus latent genome correlates with the oncogenicity by the activation level of LMP1 and NF-κB

    by Lielian Zuo, Haibo Yu, Lingzhi Liu, Yunlian Tang, Hongzhuan Wu, Jing Yang, Meijuan Zhu, Shujuan Du, Lian Zhao, Li Cao, et al.

    The copy number of Epstein-Barr virus latent genome correlates with the oncogenicity by the activation level of LMP1 and NF-κB


  • Open Access

    miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1

    by Zhiheng Chen, Shaojun Liu, Li Tian, Minghao Wu, Feiyan Ai, Wuliang Tang, Lian Zhao, Juan Ding, Liyang Zhang, Anliu Tang

    MiR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1


  • Analysis of the raw serum peptidomic pattern in glioma patients

    by Zheng Li, Hongmei Lu, Jing Yang, Xi Zeng, Lian Zhao, Hongdong Li, Qianjing Liao, Shuping Peng, Ming Zhou, Minghua Wu, et al.


  • Open Access

    A comparative study of anti-gastric cancer activity between aqueous extract and ethanol extract of Folium cordylines fruticosae

    by S Liu, D Cao, Z Xiao, F Liu, X Wang, L Zhao, L Tian, S Shen

    The active components in Folium Cordylines Fruticosae were extracted by heat reflux method. The solvents used were distilled water and ethanol. The effects of two types of extracts on gastric cancer cells were compared; dry extract yields were calculated, as well as the inhibition rates of gastric cancer MGC-803 cell proliferation and the colony cell counts. The micro-Kjeldahl method was used to measure the cell protein contents and to make a comprehensive comparison. The results showed that the MGC-803 cell inhibition rates of three different concentrations (32.5, 75 and 150 mg/ml) of ethanol extracts increased with the increase of concentration, which was 48.9% at a concentration of 150 mg/ml; aqueous extract of Folium Cordylines Fruticosae had very low inhibitory activity at a low concentration (32.5 mg/ml), which was remained at about 20%. After being affected by two types of extracts, cells had uneven sizes, with very low brightness, while the normal cells presented a uniform full form, with high definition. Keywords: Folium Cordylines Fruticosae Anti-gastric Cancer MGC-803 cell